We are live on ! Find out more

NRX Pharmaceuticals

NRXP

Market cap $154M

3.55 USD

-0.07

1.93%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

3.51

-0.04

1.13%

1 day

-1.93%

5 days

0.85%

1 month

0.28%

3 months

-20.05%

6 months

96.13%

Year to date

35.5%

1 year

40.87%

5 years

-97.58%

10 years

-96.3%

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Employees: 29

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 93.8%

Negative 6.3%

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

Zacks Investment Research

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago.

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product's vial connector.

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of first-cycle review of the Company's ANDA for preservative-free ketamine, announced earlier today.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer certification for a luer lock vial already used in three FDA-approved ANDA products with 11.9 million units shipped over the past 12 months without complaints, returns, adverse events, or recalls.

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute (“Kadima”).

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered, sub-millimetric image guidance is now being applied in HOPE's outpatient TMS workflows for patients with Major Depressive Disorder and other CNS conditions Milestone advances HOPE's interventional psychiatry platform and aligns with NRx's planned trial of NRX-101 in combination with robotic-enabled TMS in civilian and military treatment facilities (the SPARC-TMS trial). WILMINGTON, Del.

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and two of its subsidiaries in San Diego County Superior Court, alleging breach of contract and misrepresentation in connection with an acquisition agreement that the defendants warranted they had the financial capacity to close. The planned transaction represents a significant percentage of NRx's current market capitalization. T.

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

See News Rankings

Price charts implemented using Lightweight Charts™